Three-year survival of patients with chronic systolic heart failure due to hypertension: Analysis of prognostic factors

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 11, 2012, Pages 543-550

  Szymik, Monika ^a   Szyguła Jurkiewicz, Bozena ^a   Partyka, Robert ^a   Owczarek, Aleksander ^a   Spinczyk, Beata ^a   Chudek, Jerzy ^a   Polonśki, Lech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Arterial hypertension; Chronic systolic heart failure; Cox proportional hazard analysis; Receiver operating characteristic curve; Risk factors

Indexed keywords

ACENOCOUMAROL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; TORASEMIDE;

ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY DISEASE; CONGENITAL HEART MALFORMATION; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC DIAMETER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PROGNOSIS; SURVIVAL TIME;

EID: 84872362643     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1460     Document Type: Article

References (32)

1. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based case-control study. Am J Med. 2009; 122: 1023-1028.
2. Cohen JD. Hypertension epidemiology and economic burden: refining risk assessment to lower costs. Manag Care. 2009; 18: 51-58.
3. Funder JW. Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertens Res. 2010; 33: 872-875.
4. Mann DL. Pathophysiology of Heart Failure. In: Braunwald E, Libby P, Bonow RO, eds. Heart disease. Philadelphia, PA: Saunders ELSEVIER; 2008: 259-299.
5. Yusuf S, Cairns JA, Gamm AJ, et al. Evidence-Based Cardiology. 2 ed. London, United Kingdom, BMJ Books; 2003: 110-131.
6. Ingelsson E, Björklund-Bodegård K, Lind L, et al. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006; 295: 2859-2866.
7. Dubus I, Samuel JL, Swynghedauw B. Origins and mechanisms of heart failure in hypertensive heart disease. Eur Heart J. 1993; 14 Suppl J: 76-81.
8. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2012; 21: 46-51.
9. McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33; 1787-1847.
10. Iwańska K, Gworys P, Gawor Z. Prognostic value of NT-proBNP levels in patients undergoing permanent pacemaker implantation. Pol Arch Med Wewn. 2010; 120: 120-126.
11. Rewiuk K, Wizner B, Fedyk-Łukasik M, et al. Epidemiology and man-agement of coexisting heart failure and atrial fibrillation in an outpatient setting. Pol Arch Med Wewn. 2011; 121: 392-399.
12. Zareba W, Zareba KM. Which patients with chronic heart failure should be referred for CRT-D implantation? Practical implications of current clinical research. Pol Arch Med Wewn. 2010; 120: 95-102.
13. Pecini R, Møller DV, Torp-Pedersen C, et al. Heart failure etiology impacts survival of patients with heart failure. Int J Cardiol. 2011; 149: 211-215.
14. de Carvalho Frimm C, Soufen HN, Koike MK, et al. The long-term outcome of patients with hypertensive cardiomyopathy. J Hum Hypertens. 2005; 19: 393-400.
15. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to esti-mate GFR from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
16. Richards AM, Doughty R, Nicholls MG, et al.; Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001; 37: 1781-1787.
17. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-1675.
18. Masson S, Latini R Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; 52: 1528-1538.
19. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; 110: 2168-2174.
20. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009; 55: 53-60.
21. Stanton E, Hansen M, Wijeysundera HC, et al. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail. 2005; 7: 557-565.
22. Wedel H, McMurray JJV, Linderg M, et al.; PRAISE-2 study investigators. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur J Heart Fail. 2009; 11: 281-291.
23. Thrainsdottir IS, Aspelund T, Hardarson T, et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik study. Eur J Cardiovasc Prev Rehabil. 2005; 12: 465-471.
24. Matsue Y, Suzuki M, Nakamura R, et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J. 2011; 75: 2833-2839.
25. Countinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident of cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 1.4 years. Diabetes Care. 1999; 22: 233-240.
26. Shinagawa H, Inomata T, Koitabashi T, et al. Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. Circ J. 2008; 72: 364-369.
27. Lau GT, Tan HC, Kritharides L. Type of dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol. 2002; 90: 1405-1409.
28. Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012; 42: 153-163.
29. de Groote P, Lamblin N, Mouquet F, Bauters C. No gender survival difference in a population of patients with CHF related to left ventricular systolic dysfunction and receiving optimal medical therapy. Arch Cardiovasc Dis. 2008; 101: 242-248.
30. Martínez-Sellés M, Martínez E, Cortés M, et al. Determinants of long-term survival in patients hospitalized for heart failure. J Cardiovasc Med (Hagerstown). 2010; 11: 164-169.
31. Momose M, Okayama D, Nagamatsu H, et al. Long-term prognostic stratification by a combination of (123)I-metaiodobenzylguanidine scintigraphy and ejection fraction in dilated cardiomyopathy. Ann Nucl Med. 2011; 25: 419-424.
32. Solomon SD, Anavekar N, Skali H, et al.; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005; 112: 3738-3744.